Evidence of possible molecular crosstalk between inflammation and insulin resistance suggests that treatments for diabetes might be useful in patients with rheumatoid arthritis (RA), or vice versa. However, in a new trial of a PPARγ agonist in RA, the clinical effect was at most modest. So, does such an approach have a future?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ormseth, M. J. et al. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. Arthritis Res. Ther. 15, R110 (2013).
Freeman, D. J. et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51, 1596–1600 (2002).
Wellen, K. E. & Hotamisligil, G. S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788 (2003).
Hotamisligil, G. S. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 54 (Suppl. 2), S73–S78 (2005).
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. BMJ 342, d548 (2011).
Stavropoulos-Kalinoglou, A. et al. Anti-tumour necrosis factor α therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res. Ther. 14, R160 (2012).
Chung, E. S. et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107, 3133–3140 (2003).
Douglas, K. M. J., Sattar, N. & Kitas, G. D. Potential role of statins and PPARs in rheumatoid arthritis. Future Rheumatol. 1, 259–274 (2006).
Cariou, B., Charbonnel, B. & Staels, B. Thiazolidinediones and PPARγ agonists: time for a reassessment. Trends Endocrinol. Metab. 23, 205–215 (2012).
Ridker, P. M., Thuren, T., Zalewski, A. & Libby, P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am. Heart J. 162, 597–605 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N. Sattar declares that he has consulted for AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, MSD, Roche, Sanofi and UCB. G. D. Kitas declares that he has received speaker fees and/or consulting honouraria and/or research grants from Abbvie, AstraZeneca, BMS, Pfizer/Wyeth and UCB.
Rights and permissions
About this article
Cite this article
Sattar, N., Kitas, G. Testing the inflammation–insulin resistance link in clinical trials. Nat Rev Rheumatol 9, 702–703 (2013). https://doi.org/10.1038/nrrheum.2013.178
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2013.178